Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook
Cencora reports Q3 sales of $80.66 billion and EPS of $4.00, both above estimates, driven by GLP-1 and specialty drug demand in U.S. markets. read more
Read More
How Ethereum Treasury Companies Beat Out ETFs: Standard Chartered
Ethereum (CRYPTO: ETH) treasury companies are rapidly emerging as a compelling alternative to U.S.-listed spot Ethereum ETFs, according to a Wednes read more
Office Depot’s Parent ODP Shrinks Retail Footprint, Expands B2B Offerings
ODP delivered adjusted Q2 EPS of $0.51 versus $0.36 consensus while advancing its Optimize for Growth plan amid tariff pressures and strengthening its free cash flow outlook. read more
AMD Stock Has A Lot ‘To Be Encouraged And Excited About’: Analysts Are Cautious But Bullish
AMD analysts are cautiously optimistic on the company’s future after Q2 results. Here are the keys to the second half of 2025. Latest Ratings for AMD Date Firm Action From To Feb 2022 Bernstein Upgrades Market Perform Outperform Feb 2022 Daiwa Capital Upgrades Outperform Buy Feb 2022 Mizuho Maintains Buy View More Analyst Ratings for…
Buffett Misses The AI Boom — But Is He Just Warming Up For The Bust?
BRK underperforms: Is Warren Buffett skeptical of AI hype and now holding cash, waiting for a market crash to capitalize on bargains? read more
Palantir’s Alex Karp Tells Haters To ‘Read ‘Em And Weep’
Palantir CEO Alex Karp delivers his signature bold remarks and reflects on what he describes as “a once in a generation, truly anomalous quarter.” read more
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027
Edwards Lifesciences may avoid bearishness but is likely to trade sluggishly through 2027, as key cycle phases signal limited upside potential. read more
